Dyne Therapeutics
118 hedge funds and large institutions have $666M invested in Dyne Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 24 closing their positions.
104% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 28
6% more capital invested
Capital invested by funds: $629M → $666M (+$37.1M)
4.55% more ownership
Funds ownership: 96.96% → 101.51% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less funds holding
Funds holding: 127 → 118 (-9)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
74% less call options, than puts
Call options by funds: $46K | Put options by funds: $179K
Top Buyers
| 1 |
VA
VR Adviser
New York
|
+$25.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.1M |
| 4 |
AC
Armistice Capital
New York
|
+$10.8M |
| 5 |
BlackRock
New York
|
+$8.29M |
Top Sellers
DYN Hedge Fund Activity: Q2 2023 in Review
118 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2023, worth a combined $666M — up 5.9% from $629M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of DYN and 15 opened new positions — a net loss of 9 holders — while 28 trimmed existing stakes and 57 added.
The largest buyer was VR Adviser, opening a new position worth an estimated $25.6M. The largest seller was EcoR1 Capital, cutting an estimated $18M.
- 118 institutional investors held Dyne Therapeutics (DYN) as of Q2 2023, down from 127 in Q1 2023.
- Funds reported $666M of Dyne Therapeutics stock for Q2 2023, up 5.9% quarter-over-quarter.
- 15 funds opened new Dyne Therapeutics positions in Q2 2023 and 24 closed out, a net change of -9 holders.
- The largest Dyne Therapeutics buyer in Q2 2023 was VR Adviser, an estimated $25.6M added.
- The largest Dyne Therapeutics seller in Q2 2023 was EcoR1 Capital, an estimated $18M sold.
Based on aggregated 13F filings for Q2 2023.